BMT can both transmit and eliminate autoimmune diseases, and hence it has been suggested as an optional treatment for severe autoimmune conditions. In this communication we deal with the question of whether chronic GVHD is an autoimmune disease in itself, review the literature reports of autoimmune diseases following BMT in humans, and describe the autoimmune nature of the post-BMT state. Chronic GVHD, which is a frequent complication post-BMT, has clinical and pathogenic characteristics similar to autoimmune diseases, such as scleroderma and Sjogren's syndrome. Although the pathogenesis of chronic GVHD is not yet clear, thymic damage induced by acute GVHD may contribute to both the immunodeficiency and autoimmunity characterising chronic GVHD. A similar phenomenon is syngeneic GVHD, which results from an imbalance between autoreactive and autoregulatory lymphocytes. Additionally, other autoimmune diseases have been reported in post-BMT patients, and among these the most common are hypothyroidism, hyperthyroidism, myasthenia gravis and immune cytopenias. Although these diseases also occur also outside the post-BMT setting, they are unique with respect to pathogenesis (no association between myasthenia gravis and thymic pathology), diagnosis (symptoms of hyperthyroidism may be inadvertently related to other conditions), and prognosis (post-BMT autoimmune cytopenias may be fatal and treatment non-responsive). Nevertheless, many other autoimmune diseases have been reported after BMT, and these are mainly presented as case reports. Regarding the mechanism of post-BMT autoimmunity, the minority of cases stem from donorrelated transfer of pathogenic lymphocytes or their progenitors, while most of the cases (either chronic GVHD or specific diseases) can be attributed to the immunologic imbalances characterising the post-BMT setting. The factors that may expose an individual to autoimmunity development post-BMT include genetic predisposition, an environmental factor such as CMV, and the nature of the donor who may aid in creating 
BMT is a therapeutic modality that may offer some patients with malignant or non-malignant disorders (mainly haematological, but others too) the greatest chance for cure. In short, BMT is based on destruction of the patient's BM with rescue of BM cells from a non-genetically identical donor (allogeneic transplant), genetically identical donor such as a twin sibling (syngeneic transplant), or the patient himself using BM cells which were collected prior to BM elimination (autologous transplant). The rationale behind this procedure is to eliminate the neoplastic clone within the BM cells (as is the case for patients with leukaemia), to immunosuppress the host in order to prevent graft rejection, 1 and to reconstitute the haematopoietic system with BM cells lacking the pathogenic clone, which may result in disease cure. In addition, when BMT is indicated for the treatment of leukaemia, the recipient may benefit from a GVL effect from donor T cells. 2, 3 Although BMT for the treatment of autoimmune diseases was proposed a long time ago, based on many animal models and a few human case reports, 4 it was not until recently that BMT was considered a treatment to potentially cure patients with autoimmune diseases and no associated disease necessitating BMT. If the basic defect of an autoimmune disease is within the stem cells, it may be cured in the same way that an haematological malignancy is eliminated, namely by allogeneic BMT, 5, 6 whereas if the primary defect is an aberrant immune reaction to an acquired or a self Ag, tolerance may be acquired in the newly reconstituted immune system following ABMT. 5 Regarding this, a consensus report written on behalf of the European League Against Rheumatism and the European Group for Blood and Marrow Transplantation that deals with these issues, has recently been published. 7 When considering the many factors that contribute to the mosaic of autoimmunity 8 among which are genetic, environmental and hormonal factors, it is obvious that whereas autoimmune diseases can occur as a result of antigenic cross-reactivity to an infectious agent, then the emergence of autoimmune diseases following BMT, in which the immune system is dramatically destroyed and subsequently reconstituted, is not surprising.
In this communication we deal with the question of whether chronic GVHD is an autoimmune disease in itself, review the literature reports of autoimmune diseases following BMT in humans and describe the autoimmune nature of post-BMT state.
Chronic graft-versus-host disease
Without prophylactic immunosuppression most allogeneic BMTs will be complicated by GVHD. 1 Acute GVHD is characterised by cytolytic damage of recipient skin, liver and gastrointestinal tract, and systemic symptoms including fever and increased capillary permeability, whereas chronic GVHD is characterised by fibrosis of the skin, liver, lungs and gastrointestinal tract, immunodeficiency and production of autoantibodies. 9 Requirements for the development of GVHD are in general:
1 (1) The graft must contain immunologically competent cells. (2) The recipient must express tissue antigens that are not present in the transplant donor. (3) The recipient must be incapable of mounting an effective response to destroy the transplanted cells. These requirements provide a good explanation for the immunopathophysiology of acute GVHD in which clonal proliferation and differentiation of T cells occur after Ag presentation and activation of individual T cells; these T cells release multiple interleukins in a dysregulated fashion resulting in activation of secondary effectors which damage recipient target tissues. 6 In contrast, the pathogenesis of chronic GVHD is less clear: its clinical features in humans, combined with the results of experimental studies, strongly support the assumption that it results from an underlying autoimmune mechanism.
Clinical and laboratory autoimmune features of chronic graft-versus-host disease
Chronic GVHD occurs in 25%-70% of patients undergoing allogeneic BMT, despite GVHD prophylaxis. 10 In one series of patients, Rouquette-Gally et al 11 reported 40 out of 53 long-term survivors after allogeneic BMT, who displayed chronic GVHD with clinical features of scleroderma, Sjogren's syndrome and autoimmune hepatitis. Indeed, 80% of chronic GVHD patients have skin changes that in severe cases may resemble scleroderma, with induration, joint contractures, atrophy, and chronic skin ulcers. 1 Additionally, sicca syndrome may accompany chronic GVHD, with atrophy and dryness of mucosal surfaces which usually affects the eyes, mouth, airways, skin and oesophagus; chronic cholestatic liver disease occurs in up to 80% of patients. 1 Besides the clinical features associated with autoimmune diseases, many patients who have undergone BMT develop various autoantibodies. Rouquette-Gally et al 11 found an increased prevalence of autoantibodies in 53 long-term survivors after allogeneic BMT: anti-nuclear, anti-smooth muscle, anti-mitochondria, anti-liver microsomes and antiepidermal antibodies were found at a frequency of 62.2, 49.0, 11.3, 5.6 and 11.3%, respectively. Screening for native anti-DNA, anti-extractable nuclear antigens, anticentromer and anti-salivary gland duct antibodies was negative. Similar but not entirely parallel results have been reported by others: Lister et al 12 found among 26 patients with GVHD antinuclear factor, anti-double-stranded DNA, anti-smooth muscle and anti-nucleoli antibodies in 39, 15, 41 and 22% of patients, respectively, whereas Holmes et al 13 reported no antibodies to single-and double-stranded DNA, IgG antibodies to cardiolipin, IgG antinuclear and anti-cytoplasmic factors or IgM rheumatoid factor among 16 and 19 patients who had received autologous or allogeneic transplants, respectively. However, IgM anti-cytoplasmic factor was positive in 37 and 20% of allogeneic and autologous groups, respectively.
The pathogenesis of chronic graft-versus-host disease
Histologic examination of the immune system in chronic GVHD reveals involution of thymic epithelium, disappearance of Hassall's corpuscles, depletion of lymphocytes, and absence of secondary germinal centres in lymph nodes. 1 It is speculated that thymic damage is induced by acute GVHD as a part of the selective epithelial damage of target organs, and this may contribute to the development of chronic GVHD by reducing the capacity of the recipient thymus to support the positive selection necessary for protective immunity, and by decreasing the negative selection necessary for the normal immunoregulation of autoreactive T lymphocytes. 9 An animal model of induced GVHD emphasises that severe thymic damage, characterised by severe dysplasia, occurs shortly after GVHD induction, whereas thereafter thymic regeneration occurs.
14 This continued regeneration may create temporary conditions in which subsets of lymphocytes predominate, and if these are autoreactive, T suppressor cells may not satisfactorily control them. Other explanations for thymic dysfunction in chronic GVHD include injury to the thymus during the conditioning regimen, or age-related involution and atrophy, 1 and indeed, post-BMT autoimmunity in mice was found to be enhanced in older recipients, regardless of the age of the donors. 15 Whatever the cause of thymic damage in chronic GVHD is, it results in a decrease in the relative frequency of autoregulatory T lymphocytes, and thus an increase in the relative frequency of autocytotoxic T cells. Another finding that also supports the importance of donor T cells in the pathogenesis of both acute and chronic GVHD, is the fact that the relative risk for developing clinical chronic GVHD was found to be 2.22 among unmodified blood stem cell grafts recipients, compared with unmodified marrow grafts recipients. 16 This difference stems from the much higher number of T lymphocytes in the former than in the latter.
Another interesting phenomenon is the syngeneic GVHD that occurs in recipients of syngeneic or autologous transplants. 17 . This syndrome is usually self-limiting and affects predominantly the skin. It seems to result from an imbalance between autoreactive and autoregulatory lymphocytes that results from thymic dysfunction, similar to the pathogenic process in chronic GVHD. However, CsA which is clinically used as an immunosuppressant, can aid in autoimmunity development in this condition: following autologous or syngeneic BMT it may block the production of both autoreactive and autoregulatory T lymphocytes, while fol-lowing the cessation of its administration, the autoreactive T lymphocytes appear first, resulting in the development of syngeneic GVHD that resolves when the autoregulatory T lymphocytes appear. 9 It should be noted that thymus dysfunction has a pathogenic role in autoimmune diseases in other situations. There is a dual relationship between the thymus and autoimmune diseases: on the one hand it may protect from autoimmunity development by the negative selection which takes place, while on the other hand its presence may aid in autoimmune disease development in specific situations such as thymoma or thymic hyperplasia. 18 Furthermore, thymectomy, which is sometimes a treatment for myasthenia gravis, and less commonly for other autoimmune diseases, may also predispose to emergence of autoimmunity, as supported by many animal models. The same is also true in humans: a representative situation would be thymectomy for thymoma followed by the appearance of an autoimmune disease such as systemic lupus erythematosus. 19 Another possible mediator in the pathogenesis of chronic GVHD may be prolactin, as Hinterberger-Fischer et al 20 have reported increased serum prolactin levels beyond day 100 post-transplant in allogeneic recipients exhibiting chronic GVHD, compared with those who did not develop chronic GVHD. This finding may also have therapeutic implications, as bromocriptine (a dopamine agonist that suppresses prolactin secretion and has immunoregulatory properties 21 ) was found to have a suppressive effect in both experimental antiphospholipid syndrome and systemic lupus erythematosus. 22 It is possible that this drug could also aid chronic GVHD prevention or treatment, and further studies will confirm or refute this.
Thyroid autoimmunity
Many endocrine abnormalities including hypopituitarism, hypogonadism and hypothyroidism have been reported following BMT. 23, 24 Although the frequency of hypothyroidism has been found to be as high as 40% post-BMT, a recently published study of thyroid function abnormalities in 270 patients post-allogeneic BMT revealed the overall incidence of elevated thyroid stimulating hormone to be only 8.9%. 25 Since hypothyroidism is a well-known consequence of head and neck radiotherapy, the development of abnormal thyroid function has been largely attributed to the radiation effect and to a lesser extent to the chemotherapeutic agents used in preparative regimens, 26 and accordingly, a trend to hypothyroidism was observed with increasing radiation doses. 25 However, since thyroid abnormalities occurred in patients regardless of whether or not total body irradiation was used in the conditioning regimen, other aetiologies may also be implicated. Among these, autoimmune hypothyroidism should also be considered, as adoptive transfer of it has been described. 27 Although autoimmune hypothyroidism may exist as part of the autoimmune events in chronic GVHD, it should be noted that elevated thyroid antibodies titres have also been found in autologous transplant patients in whom neither GVHD nor adoptive transfer can take place. Therefore, even though the outcome may be similar, ie hypothyroidism post-BMT, it may result from different underlying mechanisms.
The emergence of hyperthyroidism post-BMT, as opposed to hypothyroidism, is much more rare. Reports of this phenomenon are scarce and are still presented as case reports. [28] [29] [30] [31] [32] In these cases, the aetiology of the hyperthyroidism was found to be autoimmune (ie Graves' disease), and is considered to result from the transfer of a pathogenic clone from the donor to the recipient via bone marrow cells. In favour of this presumption are the findings of clinical or sub-clinical hyperthyroidism in the donors, [28] [29] [30] 32 and the lack of any signs or symptoms of hyperthyroidism in the recipients prior to transplantation. However, although this presumption regarding disease pathogenesis is reasonable, other explanations should also be taken into consideration. These include recipient's own persistent intrathyroid lymphocyte population that may produce autoantibodies, an episode of thyroiditis related to viral infection, genetic predisposition to thyroid diseases on the basis of HLA type and family history, de novo development of autoimmune thyroiditis as part of the spectrum of chronic GVHD, and disturbed immune reconstitution post-BMT. [28] [29] [30] 32 Whatever the pathogenesis of post-BMT hyperthyroidism, one must bear in mind that reported cases might present only the 'tip of the iceberg' regarding this phenomenon, since some of the symptoms of hyperthyroidism (weight loss and deterioration in general health) may be inadvertently related to the original haematological disorder or to its drug therapy. 30 This is especially true when hyperthyroidism is clinically mild and transient, as may happen following disturbed immune reconstitution. The role of bone marrow cells in the pathogenesis of Graves' disease was recently emphasised by Yoshikawa et al 33 who succeeded in reconstituting human Graves' disease in SCID mice who were transplanted with thyroid tissue and BM cells from patients with Graves' disease. Although engraftment of thyroid tissue alone or in combination with peripheral blood cells was sufficient to produce human IgG in these mice, it was not sufficient to actually transfer Graves' disease. Therefore, it seems that even if bone marrow cells are not required in humans to transfer Graves' disease, they can at least aid in its development.
Myasthenia gravis
Myasthenia gravis is an autoimmune disease resulting from the production of autoantibodies that bind to the acetylcholine receptor of the neuromuscular endplate. 18 Though few cases of post-BMT myasthenia gravis have been documented in the literature, [34] [35] [36] [37] [38] [39] [40] [41] [42] the prevalence of autoantibodies against the acetylcholine receptor post-BMT was found to be much higher: these antibodies were present in eight of 62 patients with haematological disorders, 43 and additionally the number of bone marrow transplant patients making IgG autoantibodies directed against cardiolipin, SS-B and thyroglobulin was found to be significantly lower as compared to the number of patients making anti-acetylcholine receptor antibodies. 44 Therefore, since about 20% of patients with chronic GVHD develop autoantibodies directed against the acetylcholine receptor, 44, 45 authors have tried to identify patients at risk of developing myasthenia gravis. In a recently published review of the literature regarding post-BMT myasthenia gravis, Mackey et al 42 analysed the published case reports and concluded that each of the cases with this association was invariably associated with chronic GVHD and tapering of immunosuppression. Additionally, HLA Cw1, Cw7 and DR2 were identified at frequencies significantly above those expected from HLA Ag studies, as opposed to HLA A2, B7, B35 which have been previously reported as identifying patients at high risk for developing post-BMT myasthenia gravis but which were not shown to be statistically significant in the analysis by Mackey et al. 42 Thus, identification of the former may be a marker for an increased risk of developing post-BMT myasthenia gravis.
A comparison between post-BMT and idiopathic myasthenia gravis reveals major differences. Whereas the former is associated with the above-mentioned HLA subtypes, the latter is associated with HLA DRw3, DQw2 and B8. 18 Furthermore, whereas idiopathic myasthenia gravis is strongly associated with thymoma (a third of thymoma patients have myasthenia gravis, and about 15% of myasthenia gravis patients have thymoma), 18 there are no reports of this association in the post-BMT setting. Therefore, although thymectomy as an optional treatment is recommended for most myasthenia gravis patients, 19 it remains of questionable merit in post-BMT myasthenia gravis. It is noteworthy that over 50% of post-BMT myasthenia gravis patients were transplanted for aplastic anaemia. 42 . In spite of the fact that post-BMT myasthenia gravis has no direct relation to thymoma, aplastic anaemia is one of the most frequent disorders that may accompany this neoplasm. 18 In conclusion, since little is currently known about post-BMT myasthenia gravis, and it is still hard to predict which patients will develop it, we share other authors' recommendation of maintaining a high index of suspicion in patients with chronic GVHD in whom immunosuppression is tapered, and thus noting early signs and symptoms of myasthenia gravis prior to the emergence of a life-threatening myasthenic crisis.
Autoimmune cytopenias
Autoimmune cytopenias are probably the most common autoimmune disorders after BMT: not only have autoimmune neutropenia, thrombocytopenia and haemolytic anaemia been reported separately, but there have even been reports of patients with a combination of two of these disorders, or with a pancytopenia. [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Interestingly, these autoimmune cytopenias developed after either allogeneic or autologous, and even post-T-cell-depleted BMT. Immune cytopenia is one of the major causes of post-BMT cytopenia; when considering, for example, the pathogenesis of immune haemolytic anaemia after BMT, few different mechanisms can be found: 58, 59 (1) Major ABO/Rh incompatibility, which results in an immediate reaction between donor RBC and pre-existing recipient antibodies. Similarly, when donor isohaemoagglutinins are infused, a minor mismatch may occur. In either case, the antibodies titre gradually decreases with time. (2) Delayed haemolysis due to antibodies from the engrafting donor lymphocytes reacting against residual recipient RBCs. These antibodies arise in the first 3 weeks and usually disappear after 6 weeks post-transplant. (3) Autoimmune haemolytic anaemia -this type of haemolysis occurs in patients in whom engraftment has already taken place (8 weeks or more post-BMT). Thus, when there is evidence of donor engraftment, then immune-mediated haemolysis results from donor antibodies that react with donor RBCs, a reaction that is practically of an autoimmune nature.
Two recently published surveys 58, 59 dealing with post-BMT autoimmune haemolytic anaemia emphasise the unexpectedly high incidence of this phenomenon. As happens with hypothyroidism and anti-acetylcholine receptor autoantibodies post-BMT, milder cases of haemolysis may not be identified, and the reported incidence of autoimmune haemolysis represents only severe cases. Chen et al 59 reported an incidence of 3.1% patients with autoimmune haemolysis among 293 patients who underwent allogeneic BMT, whereas Drobyski et al 58 reported a similar incidence of 3% (7/236) in patients who underwent T cell-depleted allogeneic BMT; however, they found no cases of autoimmune haemolysis in 34 patients who received unmanipulated grafts. Chen et al 59 classified their reported cases into two groups: four patients with haemolytic anaemia of early onset beginning 2-8 months post-transplant and associated with a cold Ab, while five patients had the late-onset type beginning 6-18 months post-transplant and associated with warm Ab. Similarly, six out of the seven patients described by Drobyski et al 58 had a warm Ab, while disease onset in all patients was considered late, ranging from 7 to 25 months post-BMT (median 10 months).
Regarding treatment response and prognosis for patients with post-BMT autoimmune cytopenias, no definite conclusions can be currently drawn, except for the tendency of these cytopenias to result in life-threatening complications that often do not respond to conventional immunosuppressive therapy, compared with autoimmune cytopenias outside the setting of BMT. In general, most of the reported cases of autoimmune neutropenia do not carry a poor prognosis since Ab-mediated neutropenia usually responds well to treatment with corticosteroids, intravenous immunoglobulins, plasma exchange and splenectomy. 49, 60, 61 With respect to autoimmune haemolytic anaemia, the overall prognosis appears to be poorer: four out of seven and four out of nine patients described by Drobyski et al 58 and by Chen et al 59 respectively, died. In addition, the great majority of patients did not respond or had only partial responses to steroids, immunosuppression, plasmapheresis or splenectomy. Case reports of autoimmune pancytopenia following BMT describe either marked improvement in all three cell lines after steroids treatment, 57 normalisation of anaemia and thrombocytopenia after immunosuppressive treatment in the presence of refractory neutropenia (even to splenectomy) 56 or death due to infection. 55 In conclusion, since the number of patients with either type of autoimmune cytopenias after BMT is still small, it would be misleading to conclude that a patient with haemolytic anaemia has a poorer prognosis than that of a patient with autoimmune neutropenia. Therefore, we suggest that until larger case series are reported, patients with autoimmune cytopenias should be regarded as having a severe post-BMT complication and should be treated accordingly. It should be noted however, that an autoimmune cytopenia of any kind is usually a late complication after BMT (it develops several months post-transplant), and thus, the patients who develop it are the survivors of the risky engraftment period. This fact per se implies that these patients be included within a subgroup of transplanted patients with a pre-existing favorable prognosis.
Other autoimmune diseases
Autoimmune cytopenias, thyroid diseases and myasthenia gravis are the most common autoimmune phenomena that develop after BMT (along with the autoimmune similarity of chronic GVHD). However, other case reports of autoimmune diseases that have similarly emerged exist. Clinical details of representative examples of these very rare cases are summarised in Table 1 . These cases emphasise that any autoimmune disease can potentially appear after BMT, even without any evidence of donor-related disease transfer. Among these, perhaps the most astonishing report is that of Lambertenghi Deliliers et al 69 who reported a 36-year-old woman who underwent ABMT for myelodysplastic syndrome and subsequently developed (in chronological order): an erythematopapular skin eruption with histological features indistinguishable from these of cutaneous GVHD, autoimmune thyroiditis, autoimmune thrombocytopenic purpura, autoimmune haemolytic anaemia, and lupus anticoagulant. This case strongly suggests that the emergence of post-BMT autoimmune phenomena does not require transfer of pathogenic clones, although this may be Table 1 Case reports of various autoimmune diseases that rarely appeared post-bone marrow transplantation one of the possible causes for post-allogeneic BMT autoimmunity, as has already been discussed.
Post-bone marrow transplantation autoimmunitydonor-related disease transfer or immunological chaos?
Do all autoimmune phenomena post-BMT occur due to the same mechanism? Probably not. In some cases, direct transfer of either pathogenic lymphocytes, or haematopoietic stem cells committed to lymphoid lineages that will generate autoreactive clones from the donor, can result in development of autoimmune disease, and in these cases a pathogenic clonal B cell expansion that produces autoantibodies can sometimes be demonstrated. 51 Additionally, as has already been mentioned, these cases are characterised by the fact that in many of them the transferred disease can be found in the donor or among his family members, either in an active or a quiescent form. However, it seems that most of the autoimmune events after BMT (including chronic GVHD) result from an immunological dysregulation state that occurs after, and sometimes even before BMT (due to the primary disease for which BMT was indicated).
In general, the pathogenesis of autoimmune diseases is multifactorial and includes genetic, infectious, hormonal and other environmental factors. 8 These factors may also participate in post-BMT autoimmunity emergence. For example: an individual with a genetic predisposition would be more prone to develop an autoimmune disease in the post-BMT setting. A representative example is a case in which both autoimmune hypothyroidism and insulin-dependent diabetes mellitus were transferred to a bone-marrow recipient from her sister. The donor was asymptomatic at the time of the donation, but later developed both diseases. Additionally, her brother had insulin-dependent diabetes mellitus and her mother had Graves' disease. 70 Moreover, the immunodeficient state that most often accompanies early post-BMT states can allow severe infections that may consequently lead to the appearance of an autoimmune dis-ease via molecular mimicry -again, mainly in a predisposed individual. One of the candidates for this association is CMV 30, 64 that may also aid in the development of autoimmune phenomena in immunocompetent individuals. With regard to CMV, Soderberg et al [71] [72] [73] found that bone marrow transplant patients, who had either CMV disease or CMV viraemia, exclusively had CD13-specific antibodies. CD13 is a human protein that serves an important function during CMV infection and may become immunogenic if presented to the immune system as a part of the CMV virion. Anti-CD13 antibodies have not been found in healthy CMV-seropositive patients or in CMV-seronegative transplant patients. 71 Interestingly, antibodies in sera from the CD13-immune patients suffering from chronic GVHD recognised normal structures in cryosectioned skin biopsies from control individuals, producing a staining pattern similar to that of CD13-specific monoclonal antibodies. Furthermore, this pattern of binding was demonstrated in skin and oral mucosa of CD13-immune patients who had chronic GVHD. 72 Therefore, it is possible that CMV causes an autoimmune reaction that can on the one hand aid in specific autoimmune disease emergence (as a few case reports indicate), and on the other hand aid in chronic GVHD development, as skin and oral mucosa are typical regions for chronic GVHD damage. Hence, unsurprisingly Jacobson et al 74 have reported a 2-year cumulative chronic GVHD probability in BM recipients when the donor was immune to CMV pretransplant, compared with only 15% of recipients who received a transplant from a donor who was not immune to CMV. These observations carry important clinical applications: since it has been demonstrated that monoclonal antibodies can eliminate CD13-positive cells, and consequently completely inhibit CMV replication, 75 elimination of these cells in BM grafts pretransplant can decrease the risk of CMV complications, including chronic GVHD. 75 Nevertheless, it should be noted that although CMV could contribute to emergence of autoimmunity in the post-BMT setting via molecular mimicry (as opposed to hepatitis G virus, 76 for example), the fact that not all recipients who have CMV infection develop chronic GVHD or an autoimmune disease, further demonstrates that autoimmune diseases are multifactorial in etiology. CMV per se is not sufficient alone, and another contributory factor towards autoimmune problems, such as genetic predisposition, is required.
There are few other reports emphasising that BMT has a bi-directional relationship with autoimmunity: not only does a donor with an autoimmune disease sometimes fail to transfer it via BMT, 77, 78 but his disease may also be aggravated by this procedure. This is well demonstrated in the case of a donor and recipient who developed hypothyroidism almost simultaneously, 29 and that of a donor who experienced a systemic lupus erythematosus flare post donation, while the disease did not affect the recipient. 79 In these two cases it is possible that increased production and activity of immunological cells might have contributed to emergence or deterioration of the disease, as increased Ab production has been described in patients with autoimmune diseases treated with plasma exchange. 80 Another interesting feature of chronic GVHD is its clinical similarity to scleroderma. Recently, it has been suggested that scleroderma (systemic sclerosis) may actually be a form of chronic GVHD: 70.2% of female scleroderma patients had HLA class II alleles compatible either for their offspring or mother, compared with only 21% in control individuals. 81 Additionally, the mean number of male cell DNA equivalents among female scleroderma patients was much higher than in controls, 82 and Y-chromosome sequences were identified in skin biopsy specimens from 58% of women with scleroderma. 83 Hence, it can be speculated that in some patients, microchimerism, caused by class II HLA compatibility, can be involved in the pathogenesis of scleroderma. Whereas fetal or maternal cells that have crossed the placenta during pregnancy remained unrecognised by the host, subsequent activation of these cells can result in disease development. The same can be true for chronic GVHD after transplantation with HLA-compatible BM: infused T cells may later become activated and lead to emergence of chronic GVHD. It may also provide an explanation for the emergence of autoimmune diseases that are not considered to result from autoreactive clone transfer. A representative example for this association is myasthenia gravis that, as has already been mentioned, was invariably associated with chronic GVHD, and with higher frequencies of specific HLA.
Finally, one should remember that BMT is currently being used enthusiastically as an experimental treatment for patients with severe autoimmune diseases. 4 As BMT can either transfer or eliminate these diseases, it can concomitantly do both. 32 We have reported a similar phenomenon in which following thymectomy for one autoimmune disease, a 'disease switch' occurred: the first disease disappeared while the other evolved. 19 These two therapeutic interventions, thymectomy and BMT, well reflect the broad spectrum of autoimmunity.
In conclusion, BMT is a relatively risky therapeutic modality that has many indications. Among its many complications is chronic GVHD which mimics autoimmune diseases in both the pathogenesis and clinical spectrum, and specifically autoimmune diseases that may result either from donor-related pathogenic clone transfer, genetic predisposition, infection, the effects of BMT on the immune system, or a combination of these. As BMT can result in autoimmune disease transfer to the recipient, it may concomitantly cure another autoimmune disease in the recipient, or aggravate a pre-existing disease of the donor. Whenever possible, BM from a patient with an overt autoimmune disease should not be used for transplantation. However, when there is no other choice, this should be undertaken since even if the recipient develops an autoimmune disease post-transplant, his prognosis will be improved as his neoplastic disease will be eliminated by the procedure.
